Santa Clara, USA – March 26, 2026
Agilent Technologies announced U.S. FDA approval of its PD-L1 IHC 22C3 pharmDx companion diagnostic for use in patients with esophageal and gastroesophageal junction (GEJ) carcinoma, marking a significant advancement in precision oncology and biomarker-driven cancer treatment. The approval expands the use of this widely adopted diagnostic tool to help identify patients eligible for immunotherapy treatments, reinforcing the critical role of companion diagnostics in personalized medicine and clinical decision-making.
Companion Diagnostic Enhances Precision Oncology
The PD-L1 IHC 22C3 pharmDx assay is a companion diagnostic designed to measure PD-L1 expression in tumor cells, enabling clinicians to determine which patients are most likely to benefit from immune checkpoint inhibitor therapies. With this FDA approval, the test can now be used in esophageal and GEJ cancers, expanding its clinical utility across multiple tumor types.
This diagnostic plays a crucial role in guiding treatment selection, ensuring that patients receive therapies tailored to their tumor biology. By identifying PD-L1 expression levels, the assay supports the use of targeted immunotherapies, improving the likelihood of treatment success while minimizing unnecessary exposure to ineffective therapies. This aligns with the broader shift toward precision medicine and biomarker-based treatment strategies in oncology.
Strong Regulatory Milestone with Clinical Impact
Advertisement
The FDA approval represents a major regulatory milestone, highlighting the growing importance of drug-diagnostic co-development in modern healthcare. Companion diagnostics like PD-L1 IHC 22C3 pharmDx are increasingly required to support the safe and effective use of targeted cancer therapies, particularly in immuno-oncology.
The expanded indication is supported by clinical evidence demonstrating the diagnostic’s ability to accurately identify patients who may benefit from specific immunotherapies, improving clinical outcomes in difficult-to-treat cancers such as esophageal carcinoma. This advancement is particularly important given the high global burden and poor prognosis associated with these cancers, where early and precise treatment decisions can significantly impact survival rates.
Expanding Global Access to Personalized Cancer Care
Agilent continues to strengthen its position in the companion diagnostics market, supporting the global adoption of personalized oncology solutions. The PD-L1 IHC 22C3 pharmDx assay is already widely used in multiple cancer indications, and this latest approval further expands its role in clinical oncology practice.
By enabling accurate patient stratification and targeted therapy selection, the diagnostic contributes to more efficient healthcare delivery and improved patient outcomes. The approval also reflects ongoing advancements in diagnostic innovation, regulatory science, and integrated healthcare approaches, where diagnostics and therapeutics work together to optimize treatment strategies.
Overall, the FDA approval of Agilent’s PD-L1 IHC 22C3 pharmDx underscores the growing importance of companion diagnostics in oncology, regulatory compliance, and precision medicine, positioning the company at the forefront of biomarker-driven cancer care. As the oncology landscape continues to evolve, such innovations are expected to play a key role in improving treatment accuracy, patient outcomes, and healthcare system efficiency, ultimately advancing the future of cancer therapy.
Source: Agilent Technologies press release
